MX337190B - Nuevas bencensulfonamidas como bloqueadores del canal de calcio. - Google Patents
Nuevas bencensulfonamidas como bloqueadores del canal de calcio.Info
- Publication number
- MX337190B MX337190B MX2011007496A MX2011007496A MX337190B MX 337190 B MX337190 B MX 337190B MX 2011007496 A MX2011007496 A MX 2011007496A MX 2011007496 A MX2011007496 A MX 2011007496A MX 337190 B MX337190 B MX 337190B
- Authority
- MX
- Mexico
- Prior art keywords
- calcium channel
- benzenesulfonamides
- novel
- channel blockers
- formula
- Prior art date
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title 1
- 150000008331 benzenesulfonamides Chemical class 0.000 title 1
- 239000000480 calcium channel blocker Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14489909P | 2009-01-15 | 2009-01-15 | |
| PCT/US2010/020964 WO2010083264A1 (en) | 2009-01-15 | 2010-01-14 | Novel benzenesulfonamides as calcium channel blockers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011007496A MX2011007496A (es) | 2011-08-04 |
| MX337190B true MX337190B (es) | 2016-02-16 |
Family
ID=41796157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011007496A MX337190B (es) | 2009-01-15 | 2010-01-14 | Nuevas bencensulfonamidas como bloqueadores del canal de calcio. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8101614B2 (https=) |
| EP (1) | EP2382191B1 (https=) |
| JP (1) | JP5619773B2 (https=) |
| KR (1) | KR20110110299A (https=) |
| CN (1) | CN102282131B (https=) |
| AR (1) | AR077440A1 (https=) |
| AU (1) | AU2010204753A1 (https=) |
| BR (1) | BRPI1005675A2 (https=) |
| CA (1) | CA2747752A1 (https=) |
| CL (1) | CL2011001714A1 (https=) |
| CO (1) | CO6400194A2 (https=) |
| DO (1) | DOP2011000217A (https=) |
| ES (1) | ES2527467T3 (https=) |
| IL (1) | IL213500A0 (https=) |
| MX (1) | MX337190B (https=) |
| PE (1) | PE20120126A1 (https=) |
| RU (1) | RU2011134052A (https=) |
| SG (1) | SG172308A1 (https=) |
| TW (1) | TW201028421A (https=) |
| UY (1) | UY32384A (https=) |
| WO (1) | WO2010083264A1 (https=) |
| ZA (1) | ZA201104715B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009131065A1 (ja) | 2008-04-24 | 2009-10-29 | 萬有製薬株式会社 | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 |
| TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| CA2848877A1 (en) * | 2011-09-15 | 2013-03-21 | Taipei Medical University | Use of indolyl and indolinvl hvdroxamates for treating heart failure or neuronal injury |
| WO2013049164A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| WO2013049174A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| US20130178477A1 (en) * | 2012-01-05 | 2013-07-11 | Abbvie Inc. | Methods of treating diabetic neuropathy using benzenesulfonamides |
| WO2014093337A1 (en) * | 2012-12-12 | 2014-06-19 | Abbvie, Inc. | Diazepine derivatives useful as calcium channel blockers in the treatment of pain |
| DK3044218T3 (da) * | 2013-09-10 | 2020-07-27 | Univ Texas | Terapeutiske midler til targetering af trunkerede adenomatøse polyposis coli (apc)-proteiner |
| US9700549B2 (en) | 2013-10-03 | 2017-07-11 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
| US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
| JP6957460B2 (ja) | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． | アンジェルマン症候群および関連する障害の処置方法 |
| AU2018221722B2 (en) | 2017-02-15 | 2022-02-03 | Cavion, Inc. | Calcium channel inhibitors |
| JP7321097B2 (ja) | 2017-04-26 | 2023-08-04 | カビオン・インコーポレイテッド | 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法 |
| JP7395480B2 (ja) | 2018-01-10 | 2023-12-11 | クラ セラピューティクス， エルエルシー | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| WO2020038435A1 (en) | 2018-08-24 | 2020-02-27 | Sunshine Lake Pharma Co., Ltd. | Pyridinylmethylenepiperidine derivatives and uses thereof |
| IL300798B2 (en) | 2018-10-03 | 2025-09-01 | Cavion Inc | Treatment of skeletal tremor with (r)–2-(4–isopropylphenyl)–n-(1-(5-(2,2,2–trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| AR116898A1 (es) * | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| CN114340670B (zh) | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| EP3997068A1 (en) * | 2019-07-11 | 2022-05-18 | Cura Therapeutics, LLC | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
| CN117229257B (zh) * | 2022-06-06 | 2026-01-30 | 中国药科大学 | 间氨磺酰苯甲酰胺类化合物及制法、药物组合物和应用 |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4932994B2 (ja) | 1999-04-07 | 2012-05-16 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | 抗癌性カルシウムチャンネル遮断薬 |
| TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| US7223754B2 (en) * | 2003-03-10 | 2007-05-29 | Dynogen Pharmaceuticals, Inc. | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders |
| ATE467616T1 (de) * | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase |
| JP2006523707A (ja) * | 2003-04-15 | 2006-10-19 | アストラゼネカ アクツィエボラーグ | 治療化合物 |
| EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| CA2666275A1 (en) * | 2006-10-13 | 2008-04-17 | Neuromed Pharmaceuticals Ltd. | Cyclopropyl-piperazine compounds as calcium channel blockers |
| SG185285A1 (en) * | 2007-06-03 | 2012-11-29 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| WO2009131065A1 (ja) | 2008-04-24 | 2009-10-29 | 萬有製薬株式会社 | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 |
| TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
-
2009
- 2009-12-31 TW TW098146447A patent/TW201028421A/zh unknown
-
2010
- 2010-01-14 PE PE2011001348A patent/PE20120126A1/es not_active Application Discontinuation
- 2010-01-14 RU RU2011134052/04A patent/RU2011134052A/ru not_active Application Discontinuation
- 2010-01-14 CN CN201080004675.3A patent/CN102282131B/zh not_active Expired - Fee Related
- 2010-01-14 US US12/687,465 patent/US8101614B2/en not_active Expired - Fee Related
- 2010-01-14 BR BRPI1005675A patent/BRPI1005675A2/pt not_active IP Right Cessation
- 2010-01-14 WO PCT/US2010/020964 patent/WO2010083264A1/en not_active Ceased
- 2010-01-14 CA CA2747752A patent/CA2747752A1/en active Pending
- 2010-01-14 SG SG2011045564A patent/SG172308A1/en unknown
- 2010-01-14 MX MX2011007496A patent/MX337190B/es active IP Right Grant
- 2010-01-14 AU AU2010204753A patent/AU2010204753A1/en not_active Abandoned
- 2010-01-14 JP JP2011546319A patent/JP5619773B2/ja not_active Expired - Fee Related
- 2010-01-14 KR KR1020117018567A patent/KR20110110299A/ko not_active Withdrawn
- 2010-01-14 EP EP10701070.4A patent/EP2382191B1/en active Active
- 2010-01-14 ES ES10701070.4T patent/ES2527467T3/es active Active
- 2010-01-15 AR ARP100100091A patent/AR077440A1/es not_active Application Discontinuation
- 2010-01-15 UY UY0001032384A patent/UY32384A/es not_active Application Discontinuation
-
2011
- 2011-06-12 IL IL213500A patent/IL213500A0/en unknown
- 2011-06-24 ZA ZA2011/04715A patent/ZA201104715B/en unknown
- 2011-07-07 DO DO2011000217A patent/DOP2011000217A/es unknown
- 2011-07-14 CL CL2011001714A patent/CL2011001714A1/es unknown
- 2011-08-02 CO CO11097206A patent/CO6400194A2/es not_active Application Discontinuation
- 2011-12-12 US US13/323,029 patent/US8404719B2/en active Active
-
2013
- 2013-02-04 US US13/758,615 patent/US8741899B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20130210827A1 (en) | 2013-08-15 |
| EP2382191A1 (en) | 2011-11-02 |
| CL2011001714A1 (es) | 2011-11-11 |
| US8404719B2 (en) | 2013-03-26 |
| CN102282131A (zh) | 2011-12-14 |
| AU2010204753A1 (en) | 2011-08-11 |
| CO6400194A2 (es) | 2012-03-15 |
| WO2010083264A1 (en) | 2010-07-22 |
| JP5619773B2 (ja) | 2014-11-05 |
| IL213500A0 (en) | 2011-07-31 |
| BRPI1005675A2 (pt) | 2017-06-13 |
| US20120083499A1 (en) | 2012-04-05 |
| JP2012515209A (ja) | 2012-07-05 |
| DOP2011000217A (es) | 2011-07-31 |
| CA2747752A1 (en) | 2010-07-22 |
| KR20110110299A (ko) | 2011-10-06 |
| AR077440A1 (es) | 2011-08-31 |
| CN102282131B (zh) | 2015-08-26 |
| SG172308A1 (en) | 2011-07-28 |
| MX2011007496A (es) | 2011-08-04 |
| EP2382191B1 (en) | 2014-11-12 |
| ES2527467T3 (es) | 2015-01-26 |
| PE20120126A1 (es) | 2012-03-18 |
| UY32384A (es) | 2010-08-31 |
| US8741899B2 (en) | 2014-06-03 |
| ZA201104715B (en) | 2014-01-29 |
| RU2011134052A (ru) | 2013-02-20 |
| US8101614B2 (en) | 2012-01-24 |
| US20100197693A1 (en) | 2010-08-05 |
| TW201028421A (en) | 2010-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007496A (es) | Nuevas bencensulfonamidas como bloqueadores del canal de calcio. | |
| AU2009319796A8 (en) | Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers | |
| IN2012DN03883A (https=) | ||
| MY148780A (en) | Tricyclic compounds, compositions, and methods | |
| MX2009011205A (es) | Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide. | |
| MX2013005549A (es) | Aminas heterociclicas y sus usos. | |
| NZ700928A (en) | Dna-pk inhibitors | |
| TN2011000339A1 (en) | Poly (adp-ribose) polymerase (parp) inhibitors | |
| WO2009117676A3 (en) | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase | |
| MX2012008141A (es) | Compuestos y metodos. | |
| MX2009012374A (es) | Compuestos novedosos como ligandos del receptor de canabinoides. | |
| MX2010007392A (es) | Antagonistas de trpa1. | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| TW200942535A (en) | Novel compounds as cannabinoid receptor ligands | |
| EA201171211A1 (ru) | Производные оксадиазола | |
| MY157116A (en) | Novel seh inhibitors and their use | |
| EA201001481A1 (ru) | Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4 | |
| MX2010004498A (es) | Derivados de ciclohexenoamida y su uso como antagonistas de trpv1. | |
| IN2012DN03846A (https=) | ||
| IN2015DN01230A (en) | Pyrrolopyrazoles as n type calcium channel blockers | |
| NZ706418A (en) | Azaquinazoline carboxamide derivatives | |
| MX2012005155A (es) | Compuestos de quinazolina. | |
| MX2012001449A (es) | Inhibidores de cinasas c-jun-n-terminales (jnk). | |
| MX2015002037A (es) | Ciclopentilpirazoles como bloqueadores del canal de calcio tipo n. | |
| EA201100080A1 (ru) | Фенантреноновые соединения, композиции и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ABBVIE BAHAMAS LTD. |
|
| FG | Grant or registration |